Ultragenyx Pharmaceutical Inc.’s Gross Margin at a glance
Ultragenyx Pharmaceutical Inc. reports gross margin of 86.3% for Dec 2024. The prior period recorded 89.6% (Dec 2023). Year over year the metric moved −3.3 pts (−3.7%). The rolling three-period average stands at 89.4%. Data last refreshed Dec 7, 2025, 2:54 AM.
Latest reading
86.3% · Dec 2024
YoY movement
−3.3 pts (−3.7%)
Rolling average
89.4%
Current Gross Margin
86.3%
−3.3 pts
−3.7%
Rolling average
89.4%
Latest Value
86.3%
Dec 2024
YoY Change
−3.3 pts
Absolute
YoY Change %
−3.7%
Rate of change
3-Period Avg
89.4%
Smoothed
Narrative signal
Ultragenyx Pharmaceutical Inc.’s gross margin stands at 86.3% for Dec 2024. Year-over-year, the metric shifted by −3.3 pts, translating into a −3.7% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How gross margin shapes Ultragenyx Pharmaceutical Inc.'s story
As of Dec 2024, Ultragenyx Pharmaceutical Inc. reports gross margin of 86.3%. Measure pricing power and cost of goods efficiency by reviewing historical gross margins.
Pricing versus input costs
Gross margin expands when pricing power or mix more than offset raw material and labor inflation.
Benchmark to peers
Compare margins within a sector to spot operational advantages or signs of discounting.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Ultragenyx Pharmaceutical Inc. (RARE) FAQs
Answers tailored to Ultragenyx Pharmaceutical Inc.’s gross margin profile using the latest Financial Modeling Prep data.
What is Ultragenyx Pharmaceutical Inc.'s current gross margin?
As of Dec 2024, Ultragenyx Pharmaceutical Inc. reports gross margin of 86.3%. This reading reflects the latest filings and price data for RARE.
How is Ultragenyx Pharmaceutical Inc.'s gross margin trending year over year?
Year-over-year, the figure shifts by −3.3 pts (−3.7%). Pair this context with revenue growth and free cash flow signals to gauge momentum for RARE.
Why does gross margin matter for Ultragenyx Pharmaceutical Inc.?
Gross margin tracks the percentage of revenue remaining after direct production and service delivery costs. For Ultragenyx Pharmaceutical Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Ultragenyx Pharmaceutical Inc.'s gross margin above its recent average?
Ultragenyx Pharmaceutical Inc.'s rolling three-period average sits at 89.4%. Comparing the latest reading of 86.3% to that baseline highlights whether momentum is building or fading for RARE.
How frequently is Ultragenyx Pharmaceutical Inc.'s gross margin refreshed?
Data for RARE was last refreshed on Dec 7, 2025, 2:54 AM and updates automatically every 24 hours, keeping your valuation inputs current.